Glucotrack, Inc. Files S-1 with SEC
Ticker: GCTK · Form: S-1 · Filed: Sep 16, 2024 · CIK: 1506983
| Field | Detail |
|---|---|
| Company | Glucotrack, INC. (GCTK) |
| Form Type | S-1 |
| Filed Date | Sep 16, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1, ipo-potential
TL;DR
Glucotrack (formerly Integrity Applications) filed an S-1. IPO or big news coming.
AI Summary
Glucotrack, Inc. has filed an S-1 registration statement with the SEC on September 16, 2024. The company, formerly known as Integrity Applications, Inc., is incorporated in Delaware and headquartered in Rutherford, NJ. This filing indicates a move towards public offering or significant corporate action, though specific details on the offering size or terms are not yet disclosed in this initial filing.
Why It Matters
This S-1 filing signals Glucotrack, Inc.'s intent to potentially raise capital or undergo a significant corporate event, which could impact its future operations and investor landscape.
Risk Assessment
Risk Level: medium — An S-1 filing is a preliminary step for public offerings or significant corporate actions, carrying inherent market and execution risks.
Key Numbers
- 333-282158 — SEC File Number (Identifies the specific registration statement with the SEC.)
- 3841 — SIC Code (Indicates the company operates in the Surgical & Medical Instruments & Apparatus industry.)
Key Players & Entities
- Glucotrack, Inc. (company) — Registrant
- September 16, 2024 (date) — Filing Date
- Integrity Applications, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- Rutherford, NJ (location) — Principal Executive Offices
- Paul Goode (person) — Chief Executive Officer
FAQ
What is the primary purpose of this S-1 filing for Glucotrack, Inc.?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public, indicating potential for an IPO or other public offering.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the SEC on September 16, 2024.
What was Glucotrack, Inc.'s former company name?
Glucotrack, Inc. was formerly known as Integrity Applications, Inc.
Where are Glucotrack, Inc.'s principal executive offices located?
Glucotrack, Inc.'s principal executive offices are located at 301 Rte. 17 North, Ste. 800, Rutherford, NJ 07070.
Who is listed as the Chief Executive Officer of Glucotrack, Inc. in this filing?
Paul Goode is listed as the Chief Executive Officer of Glucotrack, Inc.
Filing Stats: 4,541 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-09-16 17:26:57
Key Financial Figures
- $0.001 — o shares of our common stock, par value $0.001 per share (the “Common Stock&rdqu
Filing Documents
- forms-1.htm (S-1) — 532KB
- ex23-1.htm (EX-23.1) — 7KB
- ex107.htm (EX-FILING FEES) — 12KB
- ex23-1_001.jpg (GRAPHIC) — 5KB
- 0001493152-24-036440.txt ( ) — 676KB
- ex107_htm.xml (XML) — 3KB
SELECTED FINANCIAL DATA
SELECTED FINANCIAL DATA 12
USE OF PROCEEDS
USE OF PROCEEDS 13 DIVIDEND POLICY 13 CAPITALIZATION 13
DESCRIPTION OF SECURITIES WE ARE OFFERING
DESCRIPTION OF SECURITIES WE ARE OFFERING 15 PLAN OF DISTRIBUTION 18 LEGAL MATTERS 20 EXPERTS 20 WHERE YOU CAN FIND MORE INFORMATION 20 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 20 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we have filed with the SEC. You should rely only on the information contained in this prospectus or any related prospectus supplement. We have not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The information contained in this prospectus is accurate only on the date of this prospectus. Our business, financial condition, results of operations and prospects may have changed since such date. Other than as required under the federal securities laws, we undertake no obligation to publicly update or revise such information, whether as a result of new information, future events or any other reason. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed, or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under “ Where You Can Find More Information .” This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. Persons who come into possession o